EXPERIENCE OF TREATMENT WITH RITUXIMAB IN PATIENT WITH SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS

EXPERIENCE OF TREATMENT WITH RITUXIMAB IN PATIENT WITH SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS

Show other versions (1)

The article gives a case report on patient with severe systemic type of juvenile arthritis, refractory to treatment with classical immuno suppressants and blocker of tumor necrotizing factor Successive application of biological agent — rituximab was described. In 9 weeks, extra articular symptoms of...

Full description

Bibliographic Details
Main Authors: K.B. Isaeva, E.I. Alexeeva, R.V. Denisova, T.M. Bzarova, S.I. Valieva, A.O. Lisitsin, E.Yu. Gudkova, E.L. Semikina, E.A. Kopyl'tsova
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2009-05-01
Series:Voprosy Sovremennoj Pediatrii
Online Access:https://vsp.spr-journal.ru/jour/article/view/1131
Description
Summary:The article gives a case report on patient with severe systemic type of juvenile arthritis, refractory to treatment with classical immuno suppressants and blocker of tumor necrotizing factor Successive application of biological agent — rituximab was described. In 9 weeks, extra articular symptoms of disease and acute inflammatory lesions in joints were stopped, and functional activity of child increased. Presented case report demonstrates high effectiveness of rituximab: patient with severe systemic type of juvenile arthritis has clinical and laboratory remission of disease during 12 months.Key words: children, juvenile rheumatoid arthritis, rituximab.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(3):132-138)
ISSN:1682-5527
1682-5535

Similar Items